S 545 · 119th Congress 2025–2027

Combating Illicit Xylazine Act

Latest action · Apr 15, 2026 Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedFeb 12, 2025
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Combating Illicit Xylazine Act

This bill regulates xylazine under the Controlled Substances Act (CSA).

Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.

This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.

Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.

The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.

The bill also exempts xylazine manufacturers from the CSA's physical security requirements.

Finally, the bill requires the DEA, in coordination with the Department of Health and Human Services (HHS), to provide Congress with a report on how the agencies previously determined whether xylazine should be a controlled substance, including the full text of HHS's recommendations to the DEA for scheduling xylazine.

Cosponsors 35

Members who signed on, in the order they did. Signatures ran from Feb 12, 2025 to Jun 9, 2026; 18 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-MNAmy KlobucharOriginalFeb 12, 2025
D-NMBen Ray LujánOriginalFeb 12, 2025
R-IAChuck GrassleyOriginalFeb 12, 2025
R-MSCindy Hyde-SmithOriginalFeb 12, 2025
D-NVJacky RosenOriginalFeb 12, 2025
R-IDJames E. RischOriginalFeb 12, 2025
D-NHJeanne ShaheenOriginalFeb 12, 2025
R-ALKatie Boyd BrittOriginalFeb 12, 2025
D-NYKirsten E. GillibrandOriginalFeb 12, 2025
D-NHMargaret Wood HassanOriginalFeb 12, 2025
D-WAMaria CantwellOriginalFeb 12, 2025
D-AZMark KellyOriginalFeb 12, 2025
D-CTRichard BlumenthalOriginalFeb 12, 2025
R-FLRick ScottOriginalFeb 12, 2025
R-MSRoger F. WickerOriginalFeb 12, 2025
R-WVShelley Moore CapitoOriginalFeb 12, 2025
D-VATim KaineOriginalFeb 12, 2025
R-INTodd YoungOriginalFeb 12, 2025
D-AZRuben GallegoFeb 18, 2025
R-NCThom TillisFeb 24, 2025
D-PAJohn FettermanJul 16, 2025
D-COMichael F. BennetJul 22, 2025
R-WYCynthia M. LummisJul 23, 2025
R-NCTed BuddJul 23, 2025
I-MEAngus S. King Jr.Jul 24, 2025
R-WVJames C. JusticeSep 10, 2025
R-IDMike CrapoSep 29, 2025
R-PADavid McCormickFeb 10, 2026
R-OKJames LankfordFeb 24, 2026
R-FLAshley MoodyMar 17, 2026
R-TXJohn CornynMar 19, 2026
R-TNMarsha BlackburnMar 19, 2026
D-ILRichard J. DurbinMar 26, 2026
R-TXTed CruzMar 26, 2026
D-ORJeff MerkleyJun 9, 2026

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred Feb 12, 2025Markup Mar 26, 2026

Actions 5

Everything that happened, newest first.

  1. Apr 15, 2026Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
  2. Apr 15, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.
  3. Mar 26, 2026Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Feb 12, 2025Introduced in Senate
  5. Feb 12, 2025Read twice and referred to the Committee on the Judiciary.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 1266Combating Illicit Xylazine ActRelated billSep 16, 2026

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to prohibit certain uses of xylazine, and for other purposes.
Short Title(s) as Introduced
Combating Illicit Xylazine Act
Short Title(s) as Reported to Senate
Combating Illicit Xylazine Act

Subjects

Assigned by the Library of Congress. Policy area: Crime and Law Enforcement.

Text 2

Each version as it was printed, newest first.

  1. Apr 15, 2026Reported to Senate
  2. Feb 12, 2025Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.